Published in Eur J Clin Pharmacol on January 01, 1988
A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med (1992) 2.57
The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N Engl J Med (1995) 2.49
No further increase in asthma, hay fever and atopic sensitisation in adolescents living in Switzerland. Eur Respir J (2004) 2.45
Lung function and long term exposure to air pollutants in Switzerland. Study on Air Pollution and Lung Diseases in Adults (SAPALDIA) Team. Am J Respir Crit Care Med (1997) 2.45
Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest (1992) 2.33
Prevalence of hay fever and allergic sensitization in farmer's children and their peers living in the same rural community. SCARPOL team. Swiss Study on Childhood Allergy and Respiratory Symptoms with Respect to Air Pollution. Clin Exp Allergy (1999) 2.32
Effect of blood pressure on hemorrhage volume and survival in a near-fatal hemorrhage model incorporating a vascular injury. Ann Emerg Med (1993) 2.07
Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet (1991) 2.05
Long-term ambient air pollution and respiratory symptoms in adults (SAPALDIA study). The SAPALDIA Team. Am J Respir Crit Care Med (1999) 1.65
Consultations with adolescents: the gap between their expectations and their experiences. Acta Paediatr (2003) 1.60
Cytokine-mediated Bax deficiency and consequent delayed neutrophil apoptosis: a general mechanism to accumulate effector cells in inflammation. Proc Natl Acad Sci U S A (1999) 1.56
Validation of a rhinitis symptom questionnaire (ISAAC core questions) in a population of Swiss school children visiting the school health services. SCARPOL-team. Swiss Study on Childhood Allergy and Respiratory Symptom with respect to Air Pollution and Climate. International Study of Asthma and Allergies in Childhood. Pediatr Allergy Immunol (1997) 1.50
Comparison of midazolam and diazepam for conscious sedation in the emergency department. Ann Emerg Med (1993) 1.48
On the edge of facts and hypotheses. Respiration (2000) 1.43
The anaerobic threshold in cystic fibrosis: comparison of V-slope method, lactate turn points, and Conconi test. Pediatr Pulmonol (1998) 1.42
Respiratory health and long-term exposure to air pollutants in Swiss schoolchildren. SCARPOL Team. Swiss Study on Childhood Allergy and Respiratory Symptoms with Respect to Air Pollution, Climate and Pollen. Am J Respir Crit Care Med (1997) 1.41
[Effect of air pollutant burden on healthy children and children with lung diseases in southern Ticino]. Schweiz Med Wochenschr (1989) 1.41
Pulmonary surfactant in cystic fibrosis. Eur Respir J (1997) 1.22
Vulvovaginitis in prepubertal girls. Arch Dis Child (2003) 1.10
Comparison of responses to an asthma symptom questionnaire (ISAAC core questions) completed by adolescents and their parents. SCARPOL-Team. Swiss Study on Childhood Allergy and Respiratory Symptoms with respect to Air Pollution. Pediatr Pulmonol (1998) 1.08
Vaginal foreign bodies. J Paediatr Child Health (2004) 1.08
Mastitis in early infancy. Acta Paediatr (2005) 1.04
Trends in prevalence of asthma, allergic rhinitis and atopic dermatitis in 5-7-year old Swiss children from 1992 to 2001. Allergy (2006) 1.03
Recombinant secretory leukoprotease inhibitor augments glutathione levels in lung epithelial lining fluid. J Appl Physiol (1985) (1993) 1.02
Feasibility of robotic-assisted locomotor training in children with central gait impairment. Dev Med Child Neurol (2007) 1.00
International comparison of asthma prevalence in children: Australia, Switzerland, Chile. Pediatr Pulmonol (1993) 1.00
Surfactant protein A and other bronchoalveolar lavage fluid proteins are altered in cystic fibrosis. Eur Respir J (2001) 0.99
Differential IgE recognition of recombinant Aspergillus fumigatus allergens by cystic fibrosis patients with allergic bronchopulmonary aspergillosis or Aspergillus allergy. Eur J Immunol (1998) 0.95
Associations between lung function and estimated average exposure to NO2 in eight areas of Switzerland. The SAPALDIA Team. Swiss Study of Air Pollution and Lung Diseases in Adults. Epidemiology (1998) 0.94
Family history of atopy and clinical course of RSV infection in ambulatory and hospitalized infants. Pediatr Pulmonol (2000) 0.91
The Yentl syndrome in childhood asthma: risk factors for undertreatment in Swiss children. Pediatr Pulmonol (1995) 0.90
The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma. Eur Respir J (2005) 0.90
Identification of allergic bronchopulmonary aspergillosis in cystic fibrosis patients by recombinant Aspergillus fumigatus I/a-specific serology. Am J Respir Crit Care Med (1995) 0.89
High altitude climate therapy reduces peripheral blood T lymphocyte activation, eosinophilia, and bronchial obstruction in children with house-dust mite allergic asthma. Pediatr Pulmonol (1994) 0.89
Improvement of walking abilities after robotic-assisted locomotion training in children with cerebral palsy. Arch Dis Child (2009) 0.88
DeltaF508 heterozygosity and asthma. Lancet (1998) 0.88
A new baby-spacer device for aerosolized bronchodilator administration in infants with bronchopulmonary disease. Eur J Pediatr (1992) 0.87
Reduced proteolysis of surfactant protein A and changes of the bronchoalveolar lavage fluid proteome by inhaled alpha 1-protease inhibitor in cystic fibrosis. Electrophoresis (2001) 0.86
Toxic psychosis from transdermal scopolamine in a child. Lancet (1986) 0.86
Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis. J Pediatr (1996) 0.86
Effect of environmental tobacco smoke exposure on respiratory symptoms in children. SCARPOL Team. Swiss Study on Childhood Allergy and Respiratory Symptoms with Respect to Air Pollution, Climate and Pollen. Schweiz Med Wochenschr (1999) 0.83
Interfering factors to sensitivity and specificity of bronchial reactivity in children. Pediatr Allergy Immunol (1993) 0.82
Dose-response relationships and time course of the response to systemic beta adrenoreceptor agonists in infants with bronchopulmonary disease. Thorax (1988) 0.82
Clinical and physiological improvement after inhalation of low-dose beclomethasone dipropionate and salbutamol in wheezy infants. Respiration (1997) 0.82
Genotype-phenotype association in infants with cystic fibrosis at the time of diagnosis. Pediatr Res (1998) 0.81
[Epidemiologic aspects of bronchial asthma in childhood]. Schweiz Med Wochenschr (1986) 0.81
Is there a benefit from routine voiding cystourethrography after ureterocystoneostomy? Eur J Pediatr Surg (2007) 0.80
Dosage regimens for inhaled therapy in children should be reconsidered. J Paediatr Child Health (2002) 0.80
Effect of 3 weeks' rehabilitation on neutrophil surface antigens and lung function in cystic fibrosis. Eur Respir J (2000) 0.79
Ventilatory inequalities, pulmonary function and blood oxygenation in advanced states of cystic fibrosis. Respiration (1990) 0.79
Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Arch Dis Child (2003) 0.79
Occupational exposure to inhalative irritants and methacholine responsiveness. Scand J Work Environ Health (2000) 0.79
Factors affecting the efficiency of aerosol therapy with pressurised metered-dose inhalers through plastic spacers. Swiss Med Wkly (2001) 0.79
High morbidity and mortality in cystic fibrosis patients compound heterozygous for 3905insT and deltaF508. Eur Respir J (2001) 0.78
The calcium hypothesis of cystic fibrosis. Cell Calcium (1984) 0.78
Oral bleeding: Child abuse alert. J Paediatr Child Health (2002) 0.78
Evaluation of a clinical algorithm involving serum eosinophil cationic protein for guiding the anti-inflammatory treatment of bronchial asthma in childhood. Pediatr Allergy Immunol (2000) 0.78
Intracellular free calcium levels in mononuclear cells of patients with cystic fibrosis and normal controls. Cell Calcium (1987) 0.78
Bronchial constriction after nebulized tobramycin preparations and saline in patients with cystic fibrosis. Eur J Pediatr (1996) 0.78
Skin test reactivity to recombinant Aspergillus fumigatus allergen I/a in patients with cystic fibrosis. Int Arch Allergy Immunol (1996) 0.77
[Swiss registry for patients with cystic fibrosis: design, programming, implementation and first examples of use]. Schweiz Med Wochenschr (2000) 0.77
Inhalation of alpha(1)-protease inhibitor in cystic fibrosis does not affect surfactant convertase and surface activity. Pulm Pharmacol Ther (2001) 0.77
Mycobacterium genavense invasive infection in two children with AIDS: long-term followup. Eur J Pediatr (1995) 0.77
Chronic metabolic alkalosis: not uncommon in young children with severe cystic fibrosis. Am J Nephrol (1995) 0.76
The relationship of serum-eosinophil cationic protein and eosinophil count to disease activity in children with bronchial asthma. Pediatr Allergy Immunol (1998) 0.76
[PFAPA syndrome: periodic fever, adenitis, pharyngitis and aphthous stomatitis]. Schweiz Med Wochenschr (1997) 0.76
Hypersensitivity pneumonitis in a five-year-old boy: an unusual antigen source. Pediatr Pulmonol (2002) 0.76
Fosfomycin for the initial treatment of acute haematogenous osteomyelitis. Arch Dis Child (2003) 0.76
Early diagnosis of cystic fibrosis by means of sweat microosmometry. J Pediatr (1984) 0.76
Comparison of different inhalation schedules to control childhood asthma. Agents Actions Suppl (1993) 0.76
Cystic fibrosis associated with neuronal intestinal dysplasia type B: a case report. J Pediatr Surg (1996) 0.75
Modulation of cytosolic free calcium levels by extracellular phosphate and lanthanum. Proc Natl Acad Sci U S A (1987) 0.75
Antipyretic effect of parenteral paracetamol (propacetamol) in pediatric oncologic patients: a randomized trial. Pediatr Hematol Oncol (1997) 0.75
Serum IgG titres against Pseudomonas aeruginosa. Arch Dis Child (1993) 0.75
[Nothing is more damaging to new truth than an old misconception. Goethe, Wilhelm Meisters Wanderjahre]. Praxis (Bern 1994) (2004) 0.75
Influence of MMR-vaccinations and diseases on atopic sensitization and allergic symptoms in Swiss schoolchildren. Pediatr Allergy Immunol (2004) 0.75
Dopamine-beta-hydroxylase in patients with cystic fibrosis. Eur J Pediatr (1986) 0.75
Improvement from pulmonary hyperinflation and bronchial obstruction following sympathomimetics systemically given in infants with broncho-pulmonary diseases. Z Erkr Atmungsorgane (1990) 0.75
Wearing a noseclip improves nebulised aerosol delivery. Swiss Med Wkly (2001) 0.75
Visual diagnosis: an adolescent female who has increasing hair growth. Pediatr Rev (2001) 0.75
Staphylococcus aureus septicaemia in a patient with cystic fibrosis. Eur J Pediatr (2000) 0.75
[Cystic fibrosis, a not very rare hereditary disease. Description, treatment possibilities and therapeutic concepts]. Krankenpfl J (1992) 0.75
[Persistent skin eruption after adenovirus infection]. Praxis (Bern 1994) (2003) 0.75
Bronchodilator responsiveness in a ventilator-dependent infant with severe tracheobronchomalacia. Intensive Care Med (1999) 0.75
The "wheezy infant" diagnosis, epidemiology and management. Agents Actions Suppl (1993) 0.75
Pulse oximetry, digital clubbing, and cystic fibrosis. Lancet (1987) 0.75
Quin 2 and manganese define multiple alterations in cellular calcium homeostasis in diabetic rat pancreas. Diabetes (1988) 0.75
[Cystic fibrosis: current therapy. Allergic bronchopulmonary aspergillosis (ABPA)]. Schweiz Med Wochenschr Suppl (2000) 0.75
Visual diagnosis: A family that has an itchy rash. Pediatr Rev (2000) 0.75
Unilateral exophthalmos in a 2(1/2) year old girl. Arch Dis Child (2002) 0.75
Elevated dopa levels in cystic fibrosis. N Engl J Med (1984) 0.75
Patient education in asthmatic children. Lung (1990) 0.75
[Invasive Pseudomonas aeruginosa and Ecthyma gangrenosum infection in a child without risk factors]. Arch Pediatr (1996) 0.75
Antibodies to polyclonal IgA, IgA1, and IgA2 and isotype-specific immune complexes in IgA nephropathy. J Clin Immunol (1989) 0.75
Plasma and urinary catecholamines in patients with cystic fibrosis. Pediatr Res (1985) 0.75
[Cystic fibrosis: current therapy]. Schweiz Med Wochenschr Suppl (2000) 0.75